Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 13/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium SCHEMBL9894073 | 0.90 | MDM2 (0.73) | MDM2CNR1CNR2PDE4BPDE4D | |
| SCHEMBL9893830 | 0.90 | MDM2 (0.75) | MDM2CNR1CNR2PDE4BPDE4D | |
| SCHEMBL9894071 | 0.90 | MDM2 (0.73) | MDM2CNR1CNR2PDE4BPDE4D | |
| Lithium Ion SCHEMBL9893839 | 0.88 | MDM2 (0.56) | MDM2CNR2PDE4BPDE4D | |
| Acetamide SCHEMBL27862813 | 0.88 | MDM2 (0.69) | MDM2CNR1CNR2PDE4BPDE4D | |
| SCHEMBL1437160 | 0.87 | MDM2 (0.59) | MDM2 | |
| SCHEMBL9893646 | 0.86 | MDM2 (0.58) | MDM2CNR1CNR2PDE4BPDE4D | |
| SCHEMBL1438349 | 0.82 | MDM2 (0.61) | MDM2CNR1PDE4BPDE4D | |
| SCHEMBL9893624 | 0.81 | MDM2 (0.52) | MDM2 | |
| SCHEMBL27862804 | 0.80 | MDM2 (0.58) | MDM2CNR1PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885CNR1 2104/4885CNR2 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.